Continuous‐Time Markov Population PK/PD Modeling of Longitudinal EASI Categorical Score in Atopic Dermatitis Treated With Rocatinlimab, an Anti‐OX40 Monoclonal Antibody
CPT: Pharmacometrics & Systems Pharmacology · 2025
DOI: 10.1002/psp4.70069 ↗Kurz gefasst
Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2025. Verfasst von Hiroki Okada und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Kyowa Kirin Co., Ltd, Tokyo, Japan. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Models, Biological, Antibodies, Monoclonal, Humanized, Receptors, OX40. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Rocatinlimab (AMG 451/KHK4083) is a potential T‐cell rebalancing therapy that inhibits and reduces the number of pathogenic T cells by targeting the OX40 receptor; it is associated with a progressive and sustained response for patients with moderate‐to‐severe atopic dermatitis (AD). This population pharmacokinetic‐pharmacodynamic (PPK‐PD) analysis of rocatinlimab analyzed the longitudinal relationship between drug exposure and response using a four‐state continuous‐time Markov model. The model was developed using a two‐compartment PPK model for exposure based on five clinical studies and the categorical scores of Eczema Area and Severity Index (EASI) response from two clinical studies in AD (NCT03096223/NCT03703102). EASI categorical score was classified by percentage reduction from baseline (EASI 0 : < 50%; EASI 50 : ≥ 50% to < 75%; EASI 75 : ≥ 75% to < 90%; EASI 90 : ≥ 90%) following rocatinlimab exposure. Overall, 413 patients/healthy subjects were included in the full PPK dataset. The observed serum concentration‐time data following rocatinlimab exposure was well described using the two‐compartment PPK model. For PPK‐PD analysis, EC 50 and E max estimates were 24.0 μg/mL (% relative standard error [RSE]: 32.4) and 1.26 (%RSE: 25.4), respectively, with dropout probability for EASI 0 (0.0291) greater than for other EASI categories. Race was identified as a covariate but was not clinically meaningful. The PPK‐PD model adequately described the time course and drug‐related change in EASI score and was used to simulate various dosage regimens to predict the time course of EASI response. The identified parameters and drug‐exposure relationship were considered to potentially support dose revisions and optimization for phase 3 trials in patients with moderate‐to‐severe AD that are utilizing a subcutaneous regimen with dosing every 4 weeks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology, Kyowa Kirin Co., Ltd, Tokyo, Japan.
- PharMax Research Inc., Irvine, California, USA.
- Clinical Pharmacology, Kyowa Kirin, Inc., Princeton, New Jersey, USA.
ORCID-Profile: Hiroki Okada, Matthew W Hruska, Andrew Gewitz, Douglas Marsteller
Zitieren
APA
Okada, H., Liao, S., Khouri, L., Liao, L., Hruska, M. W., Nagata, Y., Hasegawa, M., Gewitz, A., & Marsteller, D. (2025). Continuous‐Time Markov Population PK/PD Modeling of Longitudinal EASI Categorical Score in Atopic Dermatitis Treated With Rocatinlimab, an Anti‐OX40 Monoclonal Antibody. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70069
Vancouver
Okada H, Liao S, Khouri L, Liao L, Hruska MW, Nagata Y, et al. Continuous‐Time Markov Population PK/PD Modeling of Longitudinal EASI Categorical Score in Atopic Dermatitis Treated With Rocatinlimab, an Anti‐OX40 Monoclonal Antibody. CPT: Pharmacometrics & Systems Pharmacology. 2025. doi:10.1002/psp4.70069
BibTeX
@article{Okada2025,
author = {Okada, Hiroki and Liao, Sam and Khouri, Lisa and Liao, Lori and Hruska, Matthew W and Nagata, Yoshinori and Hasegawa, Maki and Gewitz, Andrew and Marsteller, Douglas},
title = {Continuous‐Time Markov Population PK/PD Modeling of Longitudinal EASI Categorical Score in Atopic Dermatitis Treated With Rocatinlimab, an Anti‐OX40 Monoclonal Antibody},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2025},
doi = {10.1002/psp4.70069}
}
EUVIMED